Novartis AG (DE:NOT)

XETRA:NOT

NOT

Novartis AG

RESEARCH TOOLSreports

Novartis AG (NOT) Stock Forecast & Price Target

24 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOT Analyst Ratings

Moderate Buy

7 Buy

5 Hold

2 Sell

Based on 14 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOT Stock 12 Month Forecast

Average Price Target

€133.31

▲(2.94% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Novartis AG in the last 3 months. The average price target is €133.31 with a high forecast of €152.11 and a low forecast of €103.22. The average price target represents a 2.94% change from the last price of €129.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"€76","153":"€153","95.25":"€95.3","114.5":"€114.5","133.75":"€133.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":152.11308,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€152.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":133.30538418,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€133.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.21959,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€103.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,95.25,114.5,133.75,153],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.94,134.4148523076923,135.8897046153846,137.36455692307692,138.83940923076923,140.31426153846152,141.78911384615384,143.26396615384616,144.73881846153847,146.21367076923076,147.68852307692308,149.1633753846154,150.63822769230768,{"y":152.11308,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.94,132.96810647538462,132.99621295076923,133.02431942615385,133.05242590153847,133.0805323769231,133.1086388523077,133.1367453276923,133.1648518030769,133.19295827846153,133.22106475384615,133.24917122923077,133.2772777046154,{"y":133.30538418,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.94,130.65381461538462,128.36762923076924,126.08144384615385,123.79525846153845,121.50907307692307,119.2228876923077,116.93670230769231,114.65051692307692,112.36433153846153,110.07814615384615,107.79196076923077,105.50577538461539,{"y":103.21959,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.937,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.937,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.407,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.511,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.049,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.635,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.994,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.972,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.704,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.882,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.918,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€152.11

Average Price Target€133.31

Lowest Price Target€103.22

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Evans

Kepler Capital

€115.17→€146.68

Buy

13.27%

Upside

Reiterated

04/02/26

Novartis AG (NOVN) Gets a Buy from Kepler Capital

James Quigley

Goldman Sachs

€114.08

Sell

-11.90%

Downside

Reiterated

03/31/26

Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)

Emmanuel Papadakis

Deutsche Bank

€146.68

Buy

13.27%

Upside

Reiterated

03/30/26

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

€152.11

Buy

17.46%

Upside

Reiterated

03/30/26

Buy Rating on Novartis: Durable Growth from New Therapies and Late‑Stage Pipeline Offsets Near‑Term Margin Pressure and LOE Risk

Graham Parry

Citi

€143.42

Buy

10.75%

Upside

Reiterated

03/30/26

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

€130.38

Hold

0.68%

Upside

Reiterated

03/27/26

Novartis AG (NOVN) Receives a Hold from Barclays

Thibault Boutherin

Morgan Stanley

€124.95→€146.68

Buy

13.27%

Upside

Assigned

03/26/26

Novartis: Strengthened Growth Outlook and Undervalued Late‑Stage Pipeline Support Buy Rating and Higher Target Price

Matthew Weston

UBS

€126.04

Hold

-2.67%

Downside

Reiterated

03/23/26

Novartis AG (NOVN) Receives a Hold from UBS

Rajesh Kumar

HSBC

€96.7→€103.22

Sell

-20.29%

Downside

Reiterated

03/17/26

Novartis price target raised to CHF 95 from CHF 89 at HSBCNovartis price target raised to CHF 95 from CHF 89 at HSBC

Luisa Hector

Berenberg Bank

€99.96→€119.52

Hold

-7.71%

Downside

Assigned

03/06/26

Berenberg Bank Reaffirms Their Hold Rating on Novartis AG (NOVN)

James Vane

Jefferies

€119.52

Hold

-7.71%

Downside

Reiterated

02/17/26

Jefferies Reaffirms Their Hold Rating on Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

€135.82→€146.68

Buy

13.27%

Upside

Reiterated

02/12/26

J.P. Morgan Sticks to Its Buy Rating for Novartis AG (NOVN)

Elmar Kraus

DZ BANK AG

€137.99

Hold

6.55%

Upside

Downgraded

02/09/26

DZ BANK AG downgrades Novartis AG (NOVN) to a Hold

Stephan Lingnau

Erste Group

―

Buy

―

Reiterated

01/23/26

Erste Group Sticks to Their Buy Rating for Novartis AG (NOVN)

Florent Cespedes

Bernstein

€117.34

Buy

-9.39%

Downside

Reiterated

11/20/25

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Evans

Kepler Capital

€115.17→€146.68

Buy

13.27%

Upside

Reiterated

04/02/26

Novartis AG (NOVN) Gets a Buy from Kepler Capital

James Quigley

Goldman Sachs

€114.08

Sell

-11.90%

Downside

Reiterated

03/31/26

Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)

Emmanuel Papadakis

Deutsche Bank

€146.68

Buy

13.27%

Upside

Reiterated

03/30/26

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

Sachin Jain

Bank of America Securities

€152.11

Buy

17.46%

Upside

Reiterated

03/30/26

Buy Rating on Novartis: Durable Growth from New Therapies and Late‑Stage Pipeline Offsets Near‑Term Margin Pressure and LOE Risk

Graham Parry

Citi

€143.42

Buy

10.75%

Upside

Reiterated

03/30/26

Citi Reaffirms Their Buy Rating on Novartis AG (NOVN)

James Gordon CFA

Barclays

€130.38

Hold

0.68%

Upside

Reiterated

03/27/26

Novartis AG (NOVN) Receives a Hold from Barclays

Thibault Boutherin

Morgan Stanley

€124.95→€146.68

Buy

13.27%

Upside

Assigned

03/26/26

Novartis: Strengthened Growth Outlook and Undervalued Late‑Stage Pipeline Support Buy Rating and Higher Target Price

Matthew Weston

UBS

€126.04

Hold

-2.67%

Downside

Reiterated

03/23/26

Novartis AG (NOVN) Receives a Hold from UBS

Rajesh Kumar

HSBC

€96.7→€103.22

Sell

-20.29%

Downside

Reiterated

03/17/26

Novartis price target raised to CHF 95 from CHF 89 at HSBCNovartis price target raised to CHF 95 from CHF 89 at HSBC

Luisa Hector

Berenberg Bank

€99.96→€119.52

Hold

-7.71%

Downside

Assigned

03/06/26

Berenberg Bank Reaffirms Their Hold Rating on Novartis AG (NOVN)

James Vane

Jefferies

€119.52

Hold

-7.71%

Downside

Reiterated

02/17/26

Jefferies Reaffirms Their Hold Rating on Novartis AG (NOVN)

Richard Vosser

J.P. Morgan

€135.82→€146.68

Buy

13.27%

Upside

Reiterated

02/12/26

J.P. Morgan Sticks to Its Buy Rating for Novartis AG (NOVN)

Elmar Kraus

DZ BANK AG

€137.99

Hold

6.55%

Upside

Downgraded

02/09/26

DZ BANK AG downgrades Novartis AG (NOVN) to a Hold

Stephan Lingnau

Erste Group

―

Buy

―

Reiterated

01/23/26

Erste Group Sticks to Their Buy Rating for Novartis AG (NOVN)

Florent Cespedes

Bernstein

€117.34

Buy

-9.39%

Downside

Reiterated

11/20/25

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis AG

3 Months

xxx

Success Rate

22/29 ratings generated profit

Average Return

+4.09%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.86% of your transactions generating a profit, with an average return of +4.09% per trade.

1 Year

David EvansKepler Capital

Success Rate

29/29 ratings generated profit

Average Return

+15.70%

reiterated a buy rating 8 days ago

Copying David Evans's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.70% per trade.

2 Years

xxx

Success Rate

29/29 ratings generated profit

Average Return

+29.28%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOT Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOT has received 28 Buy Ratings, 9 Hold Ratings, and 5 Sell Ratings. NOT average Analyst price target in the past 3 months is 133.31.

Each month's total comprises the sum of three months' worth of ratings.

NOT Financial Forecast

NOT Earnings Forecast

Next quarter’s earnings estimate for NOT is €1.81 with a range of €1.77 to €1.88. The previous quarter’s EPS was €1.74. NOT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.89% of the time in the same period. In the last calendar year NOT has Performed in-line its overall industry.

NOT Sales Forecast

Next quarter’s sales forecast for NOT is €11.62B with a range of €11.29B to €12.24B. The previous quarter’s sales results were €11.55B. NOT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.24% of the time in the same period. In the last calendar year NOT has Performed in-line its overall industry.

NOT Stock Forecast FAQ

What is DE:NOT’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis AG’s 12-month average price target is 133.31.

What is DE:NOT’s upside potential, based on the analysts’ average price target?

Novartis AG has 2.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis AG a Buy, Sell or Hold?

Novartis AG has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 5 hold ratings and 2 sell ratings.

What is Novartis AG’s share price target?

The average share price target for Novartis AG is 133.31. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €152.11 ,and the lowest forecast is €103.22. The average share price target represents 2.94% Increase from the current price of €129.5.

What do analysts say about Novartis AG?

Novartis AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novartis AG?

To buy shares of DE:NOT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis AG (NOT) Stock Forecast & Price Target

NOT Analyst Ratings

NOT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis AG

NOT Analyst Recommendation Trends

NOT Financial Forecast

NOT Earnings Forecast

NOT Sales Forecast

NOT Stock Forecast FAQ

Detailed List of Analyst Forecasts